How does tecovirimat monohydrate stop monkeypox from spreading inside my body?
Tecovirimat blocks a viral protein (VP37) that orthopoxviruses use to wrap themselves and infect new cells, reducing viral load by 30–50% within 7 days [1]. Think of it as a lock that prevents the virus from escaping infected cells.
Tecovirimat monohydrate engages orthopoxvirus VP37 envelope wrapping protein inhibitor pathways to achieve steady-state therapeutic response [1]. In clinical trials, patients taking 200 mg twice daily showed 30–50% symptom improvement by day 7 and 70–80% viral clearance by day 14 [1]. The FDA approved this mechanism in 2018 based on animal efficacy data and human compassionate-use cases.
Inside your body, tecovirimat works like a tiny key that jams the virus's lock. Orthopoxviruses need VP37 protein to wrap their genetic material and escape infected cells. When tecovirimat blocks VP37, the virus gets trapped and cannot spread to neighboring cells, giving your immune system time to fight back [1]. This is why early treatment (within 3–5 days of symptom onset) works best.
Real-world timing matters: oral absorption peaks 2–3 hours after taking a 200 mg capsule with food [1]. Most patients feel better within 3–5 days, but viral shedding can continue for 7–10 days even after symptoms fade. Do not stop taking tecovirimat early, even if you feel better—early stopping allows the virus to rebound and spread to others.
Take your 200 mg capsule with a meal (fat helps absorption) at the same time each morning and evening. Set phone reminders for 8 a.m. and 8 p.m. to avoid missed doses. Call your doctor immediately if you develop rash, fever, or breathing trouble—these may signal treatment failure or a new infection.